Core Insights - Hansoh Pharmaceutical has secured a significant business development (BD) deal worth up to $1.53 billion with Roche for the global rights (excluding Greater China) to its investigational CDH17-targeted antibody-drug conjugate (ADC) HS-20110 [1][2] - The deal includes an upfront payment of $80 million, potential milestone payments of up to $1.45 billion, and a share of future sales [1][2] - This transaction highlights Hansoh's strategic shift from generics to innovative drugs, with innovative drug revenue projected to account for over 80% of total revenue by mid-2025 [1][7] Business Development Strategy - Hansoh has successfully executed multiple BD transactions in the ADC field, totaling approximately $4.8 billion across three major deals, including recent agreements with GSK for other ADCs [3][4] - The company employs a dual strategy of license-in and license-out to expand its product pipeline, having completed over 20 BD transactions since 2019 [5][6] - Recent license-in agreements include collaborations with three companies to develop new drugs, with ongoing clinical trials for several candidates [6] Financial Performance - In the first half of 2025, Hansoh reported revenues of 7.434 billion yuan, a year-on-year increase of 14.27%, with net profit attributable to shareholders reaching 3.135 billion yuan, up 15.02% [7] - Sales from innovative drugs and collaborative products accounted for 82.17% of total revenue during the same period [7] Company Background - Hansoh Pharmaceutical was founded in 1995 by Sun Piaoyang and his wife Zhong Huijuan, who have played pivotal roles in the company's growth and transition from generics to innovative pharmaceuticals [8][9] - The company has a history of launching significant generic products and has now established a strong presence in the innovative drug market, with several products already on the market [5][6] Market Position - The recent BD deal with Roche and previous agreements reflect the growing trend of Chinese ADCs entering global markets, showcasing the country's R&D capabilities in this area [3][4] - Hansoh's stock has seen significant appreciation, with a 115.3% increase since the beginning of 2025, indicating strong market confidence in the company's future prospects [10]

Group 1 - The analysis focuses on various stocks and their corresponding products, highlighting the current market conditions and potential investment opportunities [1][3][4] - NIO (09866) shows a slight price recovery but remains close to the lower band of the Bollinger Bands, indicating a prevailing downtrend despite some optimistic technical signals suggesting a "buy" [3][4][5] - For NIO, there are limited product options available, with four products having exercise prices around 60-61 HKD, but investors should be prepared for a longer wait for price increases [4][5][6] Group 2 - Galaxy Entertainment (00027) has a stable price movement with a slight increase of 0.27%, but some investors anticipate a drop to around 32 HKD, which would require breaking through key support levels [8][9] - There are several products available for Galaxy Entertainment with exercise prices around 32-33 HKD, offering leverage ratios above 6, but with varying implied volatilities and premium rates [9][10] Group 3 - Oriental Selection (1797) has experienced narrow price fluctuations, currently at 24.78 HKD, with a neutral technical signal indicating no clear direction for investment [13][14] - The available products for Oriental Selection are mostly out-of-the-money, with limited options and varying conversion ratios, making it challenging for investors to find suitable products [14] Group 4 - Shanghai Electric (02727) has seen a decline in stock price, currently at 4.48 HKD, with a neutral technical signal and no corresponding put options available for bearish strategies [18][19] - Investors looking for put options for Shanghai Electric may find no suitable products, indicating a lack of options in the current market [19] Group 5 - Hansoh Pharmaceutical (03692) shows a slight price recovery but is facing bearish sentiment from investors, with no put options currently available for those looking to short the stock [19][20] - The technical signal for Hansoh is predominantly "sell," aligning with investor sentiment, but the absence of put options limits bearish strategies [20] Group 6 - SenseTime (00020) has seen a decline to 2.35 HKD, with investors anticipating further drops, and there are corresponding put options available with varying exercise prices [23][24] - The put options for SenseTime show significant differences in leverage ratios and implied volatilities, necessitating careful comparison by investors [24][25] Group 7 - Zijin Mining (02899) has experienced a slight decline, currently at 32.6 HKD, with investors predicting a potential drop to around 30 HKD, but suitable put options are limited [27][28] - The available put options for Zijin Mining have exercise prices that are too far from the current market price, making them unsuitable for investors [28][29] Group 8 - Kintor Pharmaceutical (01888) has seen a significant drop of 9.72%, with investors considering waiting for a price drop to 11 HKD before making any moves [32][33] - The only available product for Kintor has an exercise price of 12.88 HKD, limiting the options for investors looking for suitable products [33]

Core Insights - The Hong Kong Innovative Drug ETF (159567) closed down 0.46% on October 20, with a trading volume of 907 million yuan [1] - The fund was established on January 3, 2024, with an annual management fee of 0.50% and a custody fee of 0.10% [1] - As of October 17, 2024, the fund's shares totaled 8.134 billion, with a total size of 6.968 billion yuan, reflecting a significant increase in both shares and size compared to the previous year [1] Fund Performance - The fund has seen a remarkable increase of 1957.27% in shares and 1744.35% in size since December 31, 2023 [1] - The fund's cumulative trading amount over the last 20 trading days reached 27.487 billion yuan, with an average daily trading amount of 1.374 billion yuan [1] - Year-to-date, the cumulative trading amount is 224.063 billion yuan, averaging 1.173 billion yuan per day over 191 trading days [1] Fund Management - The current fund manager is Ma Jun, who has managed the fund since its inception, achieving a return of 71.34% during the management period [2] - The fund's top holdings include companies such as Innovent Biologics, WuXi Biologics, BeiGene, and others, with significant percentages of the portfolio allocated to these stocks [2]

Market Overview - The Hang Seng Index and the National Enterprises Index fell by 4.0% and 3.7% respectively last week, primarily due to tariff issues and concerns surrounding U.S. regional banks Zions and Western Alliance involved in credit fraud cases [1] - On Friday, the Hang Seng Index and the National Enterprises Index dropped by 2.5% and 2.7% respectively, with major sectors like technology, healthcare, brokerage, and automotive seeing significant declines, while gold-related stocks like Lao Pu Gold and Chow Tai Fook rose due to increasing gold prices [1] Company Performance - Chow Tai Fook reported a recovery in same-store sales growth in mainland China, Hong Kong, and Macau for Q2 (July-September), with retail value increasing by 4.1% year-on-year [1] - Insurance companies, including China Pacific Insurance and China Life, released positive profit forecasts, expecting net profit growth of 40%-60% and 50%-70% respectively for the first three quarters [2] Macroeconomic Dynamics - The Eurozone's harmonized consumer price index (CPI) for September showed a year-on-year increase of 2.2%, up 0.2 percentage points from August, aligning with Bloomberg's forecast [3] - Core consumer prices, excluding food and energy, rose by 2.4% year-on-year, exceeding both August's figures and Bloomberg's predictions by 0.1 percentage points [3] Industry Dynamics - In the gaming sector, Macau's gaming revenue for Q3 reached 62.57 billion MOP, reflecting a year-on-year increase of 12.5% and a quarter-on-quarter increase of 2.4% [4] - Despite a general decline in Hong Kong stocks due to fluctuations in U.S.-China trade relations, new consumer stocks like Lao Pu Gold performed well, rising by 18.0% last week [4] - In the automotive sector, NIO responded to GIC's allegations, stating that the related unfounded claims were investigated three years ago, with its stock rebounding by 2.1% on Friday after a 12.9% decline over the week [4] Pharmaceutical Sector - The pharmaceutical industry saw a general decline last week, influenced by U.S. Senate discussions on banning certain Chinese biotech companies from receiving federal funding and President Trump's remarks on lowering prices for popular diabetes and weight loss drugs [5] - Despite these challenges, Chinese pharmaceutical companies have made significant progress in overseas licensing, with Hansoh Pharmaceutical granting Roche rights to develop and commercialize a colorectal cancer drug outside of mainland China and Hong Kong, receiving an upfront payment of $80 million and potential milestone payments of up to $1.45 billion [5] New Energy and Utilities - The new energy and utilities sector in Hong Kong experienced a general decline, although defensive stocks like Huaneng International, China Everbright Environment, and Power Assets Holdings saw gains of 3.9%, 6.6%, and 2.1% respectively [6] - The photovoltaic sector faced notable declines, with companies like Xinyi Solar, Flat Glass Group, and GCL-Poly Energy dropping by 4.5%, 3.9%, and 0.8% respectively [6]

Core Viewpoint - The Hong Kong innovative drug sector is experiencing a positive trend with a 0.2% increase in the Hang Seng Innovative Drug Index and a significant net subscription of 21 million units for the Hang Seng Innovative Drug ETF (159316) as of 15:00 [1] Group 1: Industry Catalysts - The innovative drug industry is currently benefiting from three major catalysts: academic advancements, business development (BD) activities, and improved policy environment [1] - Domestic pharmaceutical companies such as Zai Lab and Ausun Pharma have presented their innovative drug research progress at the European Society for Medical Oncology (ESMO) conference, with Heng Rui Medicine showcasing 46 research results covering 14 innovative drugs [1] - Several companies, including Hansoh Pharmaceutical and Prizmed, have disclosed significant overseas licensing agreements focusing on key areas like Antibody-Drug Conjugates (ADC) [1] - The optimization of medical insurance, commercial insurance, and centralized procurement rules is enhancing payment and access, while domestic registration activities remain active [1] Group 2: Market Dynamics - The innovative drug sector has undergone adjustments recently, leading to improved cost-effectiveness for investors, with a resurgence of catalysts since October [1] - The Hang Seng Innovative Drug Index has excluded CXO companies, making it the first "pure" 100% innovative drug index, accurately reflecting the overall performance of Chinese innovative drug companies [1] - The Hang Seng Innovative Drug ETF (159316) is currently the only product tracking this index, providing investors with precise opportunities in the innovative drug industry [1]

Core Insights - The report indicates that the Hang Seng Index recently fell to approximately 25,247 points, influenced by ongoing tensions in US-China trade relations and short-term impacts from tariff news. The medium to long-term outlook is expected to be more affected by fundamental and policy factors [11][12]. - The report highlights that the People's Bank of China maintained the 5-year Loan Prime Rate (LPR) at 3.50% and the 1-year LPR at 3.00% in September, reflecting the market's digestion of risks related to recent antitrust laws, policies, regulations, and real estate debt in China [11][12]. - The report notes that the US President announced a 100% additional tariff on Chinese imports starting November 1, which is expected to further impact market sentiment [11]. Market Overview - The Hang Seng Index closed at 25,247 points, down 641 points or 2.48%, with a total market turnover of HKD 314.6 billion. The H-share index fell to 9,011 points, down 247 points or 2.67% [12]. - The report provides a performance overview of major indices, with the Hang Seng Index showing a year-to-date increase of 25.9%, while the H-share index increased by 23.6% [3][4]. - The report lists the best and worst performing stocks within the Hang Seng Index, with Chow Tai Fook (1929) showing a significant year-to-date increase of 151.4%, while BYD Electronics (0285) experienced a decline of 8.5% [3]. Company Analysis: Nongfu Spring (9633.HK) - Nongfu Spring reported a half-year revenue of RMB 25.6 billion for the period ending June 30, 2025, representing a year-on-year increase of 15.6%. Gross profit reached RMB 15.5 billion, up 18.6%, with a gross margin of 60.3%, an increase of 1.5 percentage points [26][27]. - The company’s net profit attributable to shareholders was RMB 7.62 billion, reflecting a year-on-year growth of 22.2%, with basic earnings per share of RMB 0.677, also up 22.0% [26]. - Nongfu Spring's total assets were approximately RMB 64.4 billion, a year-on-year increase of 21.1%, while total liabilities rose to RMB 33 billion, up 58.2% [27]. - The report notes that the company's current market valuation is lower than its historical average, with a TTM price-to-earnings ratio of approximately 41.2, compared to a 5-year average of 53.1 [27]. New Stock Dynamics - The report outlines upcoming IPOs, including Guanghe Technology (638) and Dipu Technology (1384), with expected market interest due to their moderate to large fundraising scales [30][31]. - The report provides details on the expected pricing and market capitalizations for these new listings, indicating a positive market sentiment towards these offerings [30][31].

Group 1 - The core viewpoint of the article highlights the licensing agreement between Hansoh Pharmaceutical (03692) and Roche for HS-20110 (CDH17ADC), which includes an upfront payment of $80 million and potential milestone payments of up to $1.45 billion, along with product sales sharing [1] - HS-20110 is a potential first-in-class (FIC) product currently undergoing global Phase I clinical trials for the treatment of colorectal cancer and other solid tumors in China and the United States [1] - The report indicates optimism regarding Hansoh Pharmaceutical's milestone revenue normalization and external licensing opportunities, with management raising the annual revenue guidance to a mid-to-high double-digit growth [1] Group 2 - The company is expected to achieve over 10 billion in innovative drug revenue by 2025, with the innovative drug revenue proportion likely to exceed 80% [1] - Milestone and upfront payment revenue is anticipated to exceed 2.2 billion [1] - The early pipeline includes several innovative molecules such as EGFR/cMET ADC and CDH6ADC, which have external licensing opportunities [1] Group 3 - The company is also optimistic about the continued growth of its core product, Amivantamab, in the domestic market, with four approved indications and projected sales exceeding 6 billion by 2025, with a peak single-drug sales potential of 8 billion [2] - Amivantamab in combination with chemotherapy for first-line treatment of NSCLC is expected to receive approval in the second half of the year [2] - The research pipeline includes combinations of Amivantamab with c-Met TKI and EGFR/c-Met bispecific antibodies/ADCs, which are expected to further strengthen the company's leading position in the lung cancer market [2]

Core Insights - Hansoh Pharmaceutical (03692) has signed a licensing agreement with Roche for HS-20110 (CDH17ADC), which includes an upfront payment of $80 million and potential milestone payments of up to $1.45 billion for development, regulatory approval, and commercialization progress, along with product sales sharing [1] Group 1: Licensing Agreement and Product Details - HS-20110 is a potential first-in-class (FIC) product, combining a CDH17 antibody with a topoisomerase inhibitor through a covalent bond [1] - The product is currently undergoing global Phase I clinical trials for the treatment of colorectal cancer and other solid tumors in China and the United States [1] Group 2: Revenue and Growth Projections - The report indicates optimism regarding Hansoh's milestone revenue normalization and external licensing opportunities, with the company exceeding expectations for milestone revenue in the first half of 2025 [1] - Management has raised the full-year revenue guidance to a mid-to-high double-digit growth rate, with innovative drug revenue expected to surpass 10 billion in 2025, accounting for over 80% of total revenue [1] - Milestone and upfront payment revenue is anticipated to exceed 2.2 billion [1] Group 3: Core Product Performance - The company is also optimistic about the continued growth of its core product, Amivantamab, which has received approval for four indications, with sales expected to exceed 6 billion in 2025 and a peak single-drug revenue potential of 8 billion [1] - The indication for Amivantamab in combination with chemotherapy for first-line treatment of non-small cell lung cancer (NSCLC) is expected to receive approval in the second half of the year [1] Group 4: Pipeline and Market Expansion - The early pipeline includes several innovative molecules such as EGFR/cMET ADC and CDH6ADC, which present external licensing opportunities [1] - Ongoing research and development efforts for Amivantamab in combination with c-Met TKI and EGFR/c-Met bispecific antibodies/ADCs are expected to further solidify the company's leading position in the lung cancer market [1]

Core Insights - Hansoh Pharmaceutical has entered into a licensing agreement with Roche Group's subsidiary, granting exclusive global rights for HS-20110 outside of mainland China, with an upfront payment of $80 million and potential milestone payments of up to $1.45 billion [1] - The asset HS-20110 is an investigational CDH17-targeted antibody-drug conjugate aimed at the gastrointestinal tumor market, currently undergoing Phase I clinical trials for colorectal cancer and other solid tumors in China and the US [1][2] - Hansoh has a strong track record in licensing agreements, having previously licensed two other ADC drugs to GSK in 2023, with upfront payments totaling $24.35 million and potential milestone payments exceeding $30 billion [1][2] Company Performance - As of June 2023, Hansoh Pharmaceutical has achieved over $7 billion in total licensing agreements, reflecting its robust innovation strategy initiated in 2002 [2] - The company reported a revenue of 7.434 billion yuan in the first half of 2023, a year-on-year increase of 14.3%, with a profit of 3.135 billion yuan, up 15.0% [2] - Revenue from innovative drugs and collaborative product sales reached 6.145 billion yuan, representing a 22.1% increase and accounting for 82.7% of total revenue [2] Research and Development - Hansoh has over 70 ongoing clinical trials for innovative drugs, including more than 40 candidate drugs, indicating a strong pipeline [2] - The company's R&D expenditure for the first half of 2023 was approximately 1.441 billion yuan, a 20.4% increase year-on-year, constituting about 19.4% of total revenue [2]

Macro and Strategy Research - The establishment of the Beijing Stock Exchange (BSE) in 2021 aimed to support the innovative development of small and medium-sized enterprises, resulting in 278 listed companies by 2025, with nearly 80% being small and micro enterprises and 88% being private enterprises. 72% of these companies belong to specialized and innovative sectors. In the first half of 2025, these companies achieved a total operating income of 93.35 billion yuan and a net profit attributable to shareholders of 6.12 billion yuan, with 61.5% of companies reporting revenue growth and 50.4% reporting net profit growth year-on-year [2][3]. - Despite the economic challenges of strong supply and weak demand, the BSE has shown a trend of "increasing revenue without increasing profit," with a year-on-year revenue growth rate in Q2 2025 continuing the positive growth trend since Q4 2024. However, net profit attributable to shareholders has been in continuous decline since Q4 2022, with Q2 2025 also reflecting this trend. The return on equity showed marginal improvement due to seasonal recovery in total asset turnover and leverage effects [3]. - In terms of industry performance, the upstream resource sectors showed a year-on-year decline in net profit growth, consistent with the overall trends in the A-share market. In the midstream materials sector, the basic chemical industry experienced negative growth, while the construction materials industry achieved positive growth. The construction decoration industry in the midstream manufacturing sector outperformed its A-share counterparts, while sectors like electric equipment and machinery showed negative growth. In the consumer sectors, BSE companies in beauty care and automotive performed better than their A-share counterparts, while in essential consumption, textile and apparel companies exceeded overall industry performance [3]. - Overall, BSE companies, which have a high concentration of specialized and innovative small and medium enterprises, have significant competitive differentiation in consumer sectors like beauty care and textiles. Additionally, by focusing on niche markets, BSE companies in the construction decoration sector have shown performance that exceeds industry cycles [4]. Fixed Income Research - The issuance of ultra-long special government bonds has been completed, with a total of 48 bonds issued during the period from October 10 to October 16, 2025, amounting to 625.2 billion yuan in total issuance and a net financing amount of 155.3 billion yuan. As of October 16, 2025, 37 billion yuan of new local special bonds have been issued, and 13 billion yuan of ultra-long special government bonds have been issued, completing the annual issuance plan [12][13]. - The bond yield curve has flattened slightly, with the 10-year government bond yield showing a fluctuating pattern. The relationship between stock and bond markets has become more correlated, with major stock indices and government bond yields moving in tandem [13]. Industry Research - Recent developments in the pharmaceutical and biotechnology sector include the signing of a licensing agreement between Hansoh Pharmaceutical and Roche, as well as various approvals and notifications from the National Medical Insurance Administration regarding reforms and pilot programs in traditional Chinese medicine [15]. - The overall performance of the pharmaceutical and biotechnology sector has seen a decline, with the Shanghai Composite Index dropping by 0.45% and the Shenzhen Component Index falling by 4.66%. The pharmaceutical sector specifically decreased by 2.12%, with most sub-sectors experiencing declines [15][16]. - Looking ahead, the upcoming European Society for Medical Oncology (ESMO) annual meeting is expected to provide investment opportunities through the disclosure of research results from innovative Chinese pharmaceutical companies. The third-quarter earnings reporting period is also anticipated to show gradual improvements in fundamentals, particularly in sectors benefiting from optimized procurement rules [16].